Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation.

Autor: Vo P; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA., Srinivasan R; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Purev E; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., McDuffee E; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Worthy T; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Shalabi R; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Wood K; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Wells B; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Reger R; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Stroncek D; Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Geller N; Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Aue G; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Tian X; Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Childs R; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. childsr@nhlbi.nih.gov.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Sep 09. Date of Electronic Publication: 2024 Sep 09.

Local manufacturing processes contribute to variability in human mesenchymal stromal cell expansion while growth media supplements contribute to variability in gene expression and cell function: a Biomedical Excellence for Safer Transfusion (BEST) collaborative study.

Autor: Shaz BH; Department of Pathology, Duke University, Durham, North Carolina, USA. Electronic address: beth.shaz@duke.edu., Schäfer R; Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe University Hospital, Frankfurt am Main, Germany; Institute for Transfusion Medicine and Gene Therapy, Medical Center University of Freiburg, Freiburg, Germany., Fontaine MJ; University of Maryland School of Medical Science, Baltimore, Maryland, USA., Norris PJ; Vitalant Research Institute, San Francisco, California, USA; Department of Lab Medicine, University of California San Francisco, San Francisco, California, USA., McKenna DH; Molecular and Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota, USA., Jin P; Cell Processing Section, Department of Transfusion Medicine, Clinical Center; National Institutes of Health, Bethesda, Maryland, USA., Reems JA; Cell Therapy and Regenerative Medicine Facility, University of Utah, Salt Lake City, Utah, USA., Stroncek D; Cell Processing Section, Department of Transfusion Medicine, Clinical Center; National Institutes of Health, Bethesda, Maryland, USA., Tanashi M; Japanese Red Cross Blood Service Headquarters, Tokyo, Japan., Marks D; Research and Development, Australian Red Cross Lifeblood, Sydney, NSW, Australia., Geng H; Molecular and Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota, USA., Pati S; Molecular and Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota, USA.

Publikováno v: Cytotherapy [Cytotherapy] 2024 Jun; Vol. 26 (6), pp. 531-539. Date of Electronic Publication: 2023 Dec 02.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

Autor: Kaczanowska S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Murty T; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Alimadadi A; La Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Contreras CF; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Oncology, University of Oxford, Oxford, UK., Duault C; Stanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA., Subrahmanyam PB; Stanford Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA., Reynolds W; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Gutierrez NA; La Jolla Institute for Immunology, La Jolla, CA, USA., Baskar R; Department of Pathology, Stanford University, Stanford, CA, USA., Wu CJ; Broad Institute, Cambridge, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA., Michor F; Broad Institute, Cambridge, MA, USA., Altreuter J; Broad Institute, Cambridge, MA, USA., Liu Y; Broad Institute, Cambridge, MA, USA., Jhaveri A; Broad Institute, Cambridge, MA, USA., Duong V; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Anbunathan H; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Ong C; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zhang H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Moravec R; Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu J; Dana-Farber Cancer Institute, Boston, MA, USA., Biswas R; Dana-Farber Cancer Institute, Boston, MA, USA., Van Nostrand S; Dana-Farber Cancer Institute, Boston, MA, USA., Lindsay J; Dana-Farber Cancer Institute, Boston, MA, USA., Pichavant M; Immunology Center of Georgia, Augusta University, Augusta, GA, USA., Sotillo E; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Bernstein D; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Carbonell A; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Derdak J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Klicka-Skeels J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Segal JE; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Harmon SA; Artificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Turkbey B; Artificial Intelligence Resource, Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sahaf B; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Bendall S; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Maecker H; Immunology Center of Georgia, Augusta University, Augusta, GA, USA., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA., Stroncek D; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA., Glod J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Merchant M; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hedrick CC; La Jolla Institute for Immunology, La Jolla, CA, USA; Immunology Center of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA, USA., Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Ramakrishna S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: ramakrs@stanford.edu., Kaplan RN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: rosie.kaplan@nih.gov.

Publikováno v: Cancer cell [Cancer Cell] 2024 Jan 08; Vol. 42 (1), pp. 35-51.e8. Date of Electronic Publication: 2023 Dec 21.

Liquid Storage of Peripheral Blood Stem Cell Products: Effects of Time and Temperature on Product Quality.

Autor: Tran MH; University of California, Irvine School of Medicine, Irvine, California. Electronic address: minhhat1@hs.uci.edu., Cai Y; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland., Stroncek D; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Jan; Vol. 30 (1), pp. 120.e1-120.e10. Date of Electronic Publication: 2023 Oct 04.

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.

Autor: Holland EM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Yates B; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Steinberg SM; Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Yuan CM; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Wang HW; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Annesley C; Division of Hematology and Oncology University of Washington, Seattle Children's Hospital, Seattle, Washington., Shalabi H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Stroncek D; Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland., Fry TJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, Colorado., Krueger J; Bone Marrow Transplant/Cell Therapy Section, Division of Hematology/Oncology, SickKids, Toronto, Ontario, Canada., Jacoby E; Pediatric Hemato-Oncology, Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel., Hsieh E; Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California., Bhojwani D; Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California., Gardner RA; Division of Hematology and Oncology University of Washington, Seattle Children's Hospital, Seattle, Washington., Maude SL; Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: nirali.shah@nih.gov.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2023 Sep; Vol. 29 (9), pp. 574.e1-574.e10. Date of Electronic Publication: 2023 Jun 30.